| Year |
Citation |
Score |
| 2023 |
Liang Y, Nephew KP, Hyder SM. Cholesterol Biosynthesis Inhibitor RO 48-8071 Suppresses Growth of Epithelial Ovarian Cancer Cells in Vitro and In Vivo. Journal of Cancer Science and Clinical Therapeutics. 7: 1-8. PMID 38105923 DOI: 10.26502/jcsct.5079185 |
0.42 |
|
| 2022 |
Liang Y, Besch-Williford C, Hyder SM. The estrogen receptor beta agonist liquiritigenin enhances the inhibitory effects of the cholesterol biosynthesis inhibitor RO 48-8071 on hormone-dependent breast-cancer growth. Breast Cancer Research and Treatment. 192: 53-63. PMID 35037188 DOI: 10.1007/s10549-021-06487-y |
0.504 |
|
| 2022 |
Berke TP, Slight SH, Hyder SM. Role of Reactivating Mutant p53 Protein in Suppressing Growth and Metastasis of Triple-Negative Breast Cancer. Oncotargets and Therapy. 15: 23-30. PMID 35035222 DOI: 10.2147/OTT.S342292 |
0.403 |
|
| 2019 |
Liang Y, Besch-Williford C, Cook MT, Belenchia A, Brekken RA, Hyder SM. APR-246 alone and in combination with a phosphatidylserine-targeting antibody inhibits lung metastasis of human triple-negative breast cancer cells in nude mice. Breast Cancer (Dove Medical Press). 11: 249-259. PMID 31534364 DOI: 10.2147/BCTT.S208706 |
0.581 |
|
| 2019 |
Liang Y, Besch-Williford C, Belenchia A, Brekken R, Hyder S. SUN-LB055 Targeting Mutant p53 Alone or in Combination with a Phosphatidylserine Specific Antibody Suppresses Growth and Metastasis of Human Breast Cancer: A Strategy Towards Enhancing Personalized Medicine Journal of the Endocrine Society. 3. DOI: 10.1210/Js.2019-Sun-Lb055 |
0.52 |
|
| 2018 |
Liang Y, Mafuvadze B, Besch-Williford C, Hyder SM. A combination of p53-activating APR-246 and phosphatidylserine-targeting antibody potently inhibits tumor development in hormone-dependent mutant p53-expressing breast cancer xenografts. Breast Cancer (Dove Medical Press). 10: 53-67. PMID 29606888 DOI: 10.2147/BCTT.S156285 |
0.821 |
|
| 2017 |
Liang Y, Goyette S, Hyder SM. Cholesterol biosynthesis inhibitor RO 48-8071 reduces progesterone receptor expression and inhibits progestin-dependent stem cell-like cell growth in hormone-dependent human breast cancer cells. Breast Cancer (Dove Medical Press). 9: 487-494. PMID 28744156 DOI: 10.2147/BCTT.S140265 |
0.569 |
|
| 2017 |
Goyette S, Liang Y, Mafuvadze B, Cook MT, Munir M, Hyder SM. Natural and synthetic progestins enrich cancer stem cell-like cells in hormone-responsive human breast cancer cell populations in vitro. Breast Cancer (Dove Medical Press). 9: 347-357. PMID 28579829 DOI: 10.2147/BCTT.S135371 |
0.821 |
|
| 2017 |
Cook MT, Liang Y, Besch-Williford C, Hyder SM. Luteolin inhibits lung metastasis, cell migration, and viability of triple-negative breast cancer cells. Breast Cancer (Dove Medical Press). 9: 9-19. PMID 28096694 DOI: 10.2147/BCTT.S124860 |
0.563 |
|
| 2017 |
Cook MT, Liang Y, Besch-Williford C, Hyder S. Abstract 4914: Luteolin inhibits metastasis of triple-negative breast cancer cells to the lungs Cancer Research. 77: 4914-4914. DOI: 10.1158/1538-7445.Am2017-4914 |
0.577 |
|
| 2016 |
Liang Y, Mafuvadze B, Aebi JD, Hyder SM. Cholesterol biosynthesis inhibitor RO 48-8071 suppresses growth of hormone-dependent and castration-resistant prostate cancer cells. Oncotargets and Therapy. 9: 3223-32. PMID 27313468 DOI: 10.2147/Ott.S105725 |
0.761 |
|
| 2016 |
Cook MT, Mafuvadze B, Besch-Williford C, Ellersieck MR, Goyette S, Hyder SM. Luteolin suppresses development of medroxyprogesterone acetate-accelerated 7,12-dimethylbenz(a)anthracene-induced mammary tumors in Sprague-Dawley rats. Oncology Reports. 35: 825-32. PMID 26719029 DOI: 10.3892/Or.2015.4431 |
0.8 |
|
| 2016 |
Hyder S, Cook M, Besch-Williford C, Liang Y. Abstract P1-16-06: Luteolin inhibits progestin-dependent VEGF induction, stem-cell like characteristics, and tumor progression of human breast cancer cells Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P1-16-06 |
0.703 |
|
| 2016 |
Liang Y, Aebi J, Nephew K, Hyder SM. Abstract 3789: Targeting cholesterol biosynthesis pathway to inhibit growth of drug resistant ovarian cancer cells Cancer Research. 76: 3789-3789. DOI: 10.1158/1538-7445.Am2016-3789 |
0.53 |
|
| 2016 |
Goyette S, Mafuvadze B, Cook MT, Liang Y, Hyder SM. Abstract 1807: Progestin enrichment of the cancer stem cell-like pool provides novel therapeutic targets for hormone-dependent human breast cancer Cancer Research. 76: 1807-1807. DOI: 10.1158/1538-7445.Am2016-1807 |
0.827 |
|
| 2015 |
Cook MT, Liang Y, Besch-Williford C, Goyette S, Mafuvadze B, Hyder SM. Luteolin inhibits progestin-dependent angiogenesis, stem cell-like characteristics, and growth of human breast cancer xenografts. Springerplus. 4: 444. PMID 26312209 DOI: 10.1186/S40064-015-1242-X |
0.849 |
|
| 2015 |
Liang Y, Mafuvadze B, Zou X, Besch-Williford C, Hyder SM. Abstract 5422: Inhibition of oxidosqualene cyclase blocks proliferation and survival of prostate cancer cells Cancer Research. 75: 5422-5422. DOI: 10.1158/1538-7445.Am2015-5422 |
0.767 |
|
| 2015 |
Cook MT, Liang Y, Goyette S, Mafuvadze B, Besch-Williford C, Hyder S. Abstract 4159: Therapeutic effects of luteolin against progestin-dependent breast cancer involves induction of apoptosis, and suppression of both stem-cell-like cells and angiogenesis Cancer Research. 75: 4159-4159. DOI: 10.1158/1538-7445.Am2015-4159 |
0.696 |
|
| 2015 |
Goyette S, Mafuvadze B, Cook MT, Liang Y, Hyder SM. Abstract 1867: Enrichment of CD44highstem-cell-like cells as a possible mechanism of progestin-dependent progression of human breast cancer Cancer Research. 75: 1867-1867. DOI: 10.1158/1538-7445.Am2015-1867 |
0.838 |
|
| 2014 |
Mafuvadze B, Liang Y, Hyder SM. Cholesterol synthesis inhibitor RO 48-8071 suppresses transcriptional activity of human estrogen and androgen receptor. Oncology Reports. 32: 1727-33. PMID 25051231 DOI: 10.3892/Or.2014.3332 |
0.842 |
|
| 2014 |
Liang Y, Besch-Williford C, Aebi JD, Mafuvadze B, Cook MT, Zou X, Hyder SM. Cholesterol biosynthesis inhibitors as potent novel anti-cancer agents: suppression of hormone-dependent breast cancer by the oxidosqualene cyclase inhibitor RO 48-8071. Breast Cancer Research and Treatment. 146: 51-62. PMID 24878988 DOI: 10.1007/S10549-014-2996-5 |
0.852 |
|
| 2013 |
Mafuvadze B, Cook M, Xu Z, Besch-Williford CL, Hyder SM. Effects of dietary apigenin on tumor latency, incidence and multiplicity in a medroxyprogesterone acetate-accelerated 7,12-dimethylbenz(a)anthracene-induced breast cancer model. Nutrition and Cancer. 65: 1184-91. PMID 24127693 DOI: 10.1080/01635581.2013.833637 |
0.836 |
|
| 2013 |
Neubauer H, Ruan X, Schneck H, Seeger H, Cahill MA, Liang Y, Mafuvadze B, Hyder SM, Fehm T, Mueck AO. Overexpression of progesterone receptor membrane component 1: possible mechanism for increased breast cancer risk with norethisterone in hormone therapy. Menopause (New York, N.Y.). 20: 504-10. PMID 23615641 DOI: 10.1097/Gme.0B013E3182755C97 |
0.824 |
|
| 2013 |
Carroll CE, Liang Y, Benakanakere I, Besch-Williford C, Hyder SM. The anticancer agent YC-1 suppresses progestin-stimulated VEGF in breast cancer cells and arrests breast tumor development International Journal of Oncology. 42: 179-187. PMID 23123638 DOI: 10.3892/Ijo.2012.1675 |
0.859 |
|
| 2013 |
Liang Y, Zou X, Besch-Williford C, Johannes A, Hyder SM. Abstract 871: Synthetic inhibitors of the cholesterol biosynthetic enzyme oxidosqualene cyclase block proliferation and survival of breast cancer cells. Cancer Research. 73: 871-871. DOI: 10.1158/1538-7445.Am2013-871 |
0.668 |
|
| 2013 |
Mafuvadze B, Cook M, Zhang X, Besch-Williford C, Hyder SM. Abstract 3694: Complex effects of dietary apigenin on prevention of MPA-accelerated DMBA-induced mammary tumors in Sprague-Dawley rats. Cancer Research. 73: 3694-3694. DOI: 10.1158/1538-7445.Am2013-3694 |
0.83 |
|
| 2013 |
Mafuvadze B, Manguvo A, He J, Whitney SD, Hyder SM. Breast Cancer Knowledge and Awareness among High School and College Students in Mid-Western USA International Journal of Science Education, Part B. 3: 144-158. DOI: 10.1080/09500693.2012.664294 |
0.772 |
|
| 2012 |
Mafuvadze B, Liang Y, Besch-Williford C, Zhang X, Hyder SM. Apigenin induces apoptosis and blocks growth of medroxyprogesterone acetate-dependent BT-474 xenograft tumors. Hormones & Cancer. 3: 160-71. PMID 22569706 DOI: 10.1007/S12672-012-0114-X |
0.856 |
|
| 2012 |
López Pérez FR, Liang Y, Besch-Williford CL, Mafuvadze B, Hyder SM. Differential expression of FGF family members in a progestin-dependent BT-474 human breast cancer xenograft model. Histology and Histopathology. 27: 337-45. PMID 22237711 DOI: 10.14670/Hh-27.337 |
0.793 |
|
| 2012 |
Mafuvadze B, Liang Y, Besch-Williford CL, Hyder SM. Abstract 578: Apigenin blocks medroxyprogesterone acetate-dependent progression of BT-474 human breast tumor xenografts by inducing apoptosis Cancer Research. 72: 578-578. DOI: 10.1158/1538-7445.Am2012-578 |
0.862 |
|
| 2012 |
Mafuvadze B, Manguvo A, He J, Whitney SD, Hyder SM. Abstract 4460: Breast cancer knowledge and awareness among high school and college students in mid-Western USA Cancer Research. 72: 4460-4460. DOI: 10.1158/1538-7445.Am2012-4460 |
0.776 |
|
| 2012 |
Neubauer H, Schneck H, Seeger H, Cahill M, Mueck A, Hyder S, Fehm T. 286 Overexpression of PGRMC1 n a Potential Mechanism for Increased Breast Cancer Risk During Combined Treatment with Estrogen and Norethisterone European Journal of Cancer. 48: S126. DOI: 10.1016/S0959-8049(12)70353-2 |
0.449 |
|
| 2011 |
McGee AM, Douglas DL, Liang Y, Hyder SM, Baines CP. The mitochondrial protein C1qbp promotes cell proliferation, migration and resistance to cell death Cell Cycle. 10: 4119-4127. PMID 22101277 DOI: 10.4161/Cc.10.23.18287 |
0.524 |
|
| 2011 |
Mafuvadze B, Benakanakere I, López Pérez FR, Besch-Williford C, Ellersieck MR, Hyder SM. Apigenin prevents development of medroxyprogesterone acetate-accelerated 7,12-dimethylbenz(a)anthracene-induced mammary tumors in Sprague-Dawley rats. Cancer Prevention Research (Philadelphia, Pa.). 4: 1316-24. PMID 21505181 DOI: 10.1158/1940-6207.Capr-10-0382 |
0.858 |
|
| 2011 |
Grinter SZ, Liang Y, Huang SY, Hyder SM, Zou X. An inverse docking approach for identifying new potential anti-cancer targets. Journal of Molecular Graphics & Modelling. 29: 795-9. PMID 21315634 DOI: 10.1016/J.Jmgm.2011.01.002 |
0.552 |
|
| 2011 |
Liang Y, Besch-Williford C, Benakanakere I, Thorpe PE, Hyder SM. Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors. Breast Cancer Research and Treatment. 125: 407-20. PMID 20349129 DOI: 10.1007/S10549-010-0851-X |
0.598 |
|
| 2011 |
Mafuvadze B, Benakanakere I, Lopez FR, Besch-Williford CL, Ellersieck MR, Hyder SM. Abstract 1844: Apigenin prevents development of progestin-accelerated 7,12-dimethylbenz(a) anthracene (DMBA)-induced mammary tumors in Sprague-Dawley rats Cancer Research. 71: 1844-1844. DOI: 10.1158/1538-7445.Am2011-1844 |
0.844 |
|
| 2010 |
Benakanakere I, Besch-Williford C, Carroll CE, Hyder SM. Synthetic progestins differentially promote or prevent 7,12-dimethylbenz(a) anthracene-induced mammary tumors in sprague-dawley rats Cancer Prevention Research. 3: 1157-1167. PMID 20699413 DOI: 10.1158/1940-6207.Capr-10-0064 |
0.814 |
|
| 2010 |
Mafuvadze B, Benakanakere I, Hyder SM. Apigenin blocks induction of vascular endothelial growth factor mRNA and protein in progestin-treated human breast cancer cells. Menopause (New York, N.Y.). 17: 1055-63. PMID 20551847 DOI: 10.1097/Gme.0B013E3181Dd052F |
0.829 |
|
| 2010 |
Liang Y, Benakanakere I, Besch-Williford C, Hyder RS, Ellersieck MR, Hyder SM. Synthetic progestins induce growth and metastasis of BT-474 human breast cancer xenografts in nude mice. Menopause (New York, N.Y.). 17: 1040-7. PMID 20461021 DOI: 10.1097/Gme.0B013E3181D3Dd0C |
0.612 |
|
| 2010 |
Carroll CE, Benakanakere I, Besch-Williford C, Ellersieck MR, Hyder SM. Curcumin delays development of medroxyprogesterone acetate-accelerated 7,12-dimethylbenz[a]anthracene-induced mammary tumors Menopause. 17: 178-184. PMID 19629015 DOI: 10.1097/Gme.0B013E3181Afcce5 |
0.832 |
|
| 2009 |
Liang Y, Besch-Williford C, Hyder SM. PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein. International Journal of Oncology. 35: 1015-23. PMID 19787255 DOI: 10.3892/Ijo_00000416 |
0.635 |
|
| 2009 |
Hyder SM, Liang Y, Wu J, Welbern V. Regulation of thrombospondin-1 by natural and synthetic progestins in human breast cancer cells. Endocrine-Related Cancer. 16: 809-17. PMID 19570906 DOI: 10.1677/Erc-08-0311 |
0.688 |
|
| 2009 |
Hyder SM, Liang Y, Wu J. Estrogen regulation of thrombospondin-1 in human breast cancer cells. International Journal of Cancer. 125: 1045-53. PMID 19391135 DOI: 10.1002/Ijc.24373 |
0.66 |
|
| 2009 |
Benakanakere I, Besch-Williford C, Ellersieck MR, Hyder SM. Regression of progestin-accelerated 7,12-dimethylbenz[a]anthracene-induced mammary tumors in Sprague-Dawley rats by p53 reactivation and induction of massive apoptosis: a pilot study. Endocrine-Related Cancer. 16: 85-98. PMID 19075036 DOI: 10.1677/Erc-08-0069 |
0.552 |
|
| 2008 |
Carroll CE, Ellersieck MR, Hyder SM. Curcumin inhibits MPA-induced secretion of VEGF from T47-D human breast cancer cells Menopause. 15: 570-574. PMID 18467956 DOI: 10.1097/Gme.0B013E31814Fae5D |
0.843 |
|
| 2007 |
Liang Y, Besch-Williford C, Brekken RA, Hyder SM. Progestin-dependent progression of human breast tumor xenografts: a novel model for evaluating antitumor therapeutics. Cancer Research. 67: 9929-36. PMID 17942925 DOI: 10.1158/0008-5472.Can-07-1103 |
0.701 |
|
| 2007 |
Liang Y, Besch-Williford C, Benakanakere I, Hyder SM. Re-activation of the p53 pathway inhibits in vivo and in vitro growth of hormone-dependent human breast cancer cells. International Journal of Oncology. 31: 777-84. PMID 17786308 DOI: 10.3892/Ijo.31.4.777 |
0.589 |
|
| 2007 |
Hyder SM. Sex-steroid regulation of vascular endothelial growth factor in breast cancer. Endocrine-Related Cancer. 13: 667-87. PMID 16954424 DOI: 10.1677/Erc.1.00931 |
0.609 |
|
| 2006 |
Liang Y, Brekken RA, Hyder SM. Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones. Endocrine-Related Cancer. 13: 905-19. PMID 16954439 DOI: 10.1677/Erc.1.01221 |
0.651 |
|
| 2006 |
Benakanakere I, Besch-Williford C, Schnell J, Brandt S, Ellersieck MR, Molinolo A, Hyder SM. Natural and synthetic progestins accelerate 7,12-dimethylbenz[a]anthracene-initiated mammary tumors and increase angiogenesis in Sprague-Dawley rats. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4062-71. PMID 16818706 DOI: 10.1158/1078-0432.Ccr-06-0427 |
0.484 |
|
| 2006 |
Zhou W, Liu Z, Wu J, Liu JH, Hyder SM, Antoniou E, Lubahn DB. Identification and characterization of two novel splicing isoforms of human estrogen-related receptor beta. The Journal of Clinical Endocrinology and Metabolism. 91: 569-79. PMID 16332939 DOI: 10.1210/Jc.2004-1957 |
0.327 |
|
| 2005 |
Wu J, Liang Y, Nawaz Z, Hyder SM. Complex agonist-like properties of ICI 182,780 (Faslodex) in human breast cancer cells that predominantly express progesterone receptor-B: implications for treatment resistance. International Journal of Oncology. 27: 1647-59. PMID 16273221 DOI: 10.3892/Ijo.27.6.1647 |
0.576 |
|
| 2005 |
Liang Y, Wu J, Stancel GM, Hyder SM. p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells. The Journal of Steroid Biochemistry and Molecular Biology. 93: 173-82. PMID 15860260 DOI: 10.1016/J.Jsbmb.2004.12.011 |
0.579 |
|
| 2005 |
Liang Y, Hyder SM. Proliferation of endothelial and tumor epithelial cells by progestin-induced vascular endothelial growth factor from human breast cancer cells: paracrine and autocrine effects. Endocrinology. 146: 3632-41. PMID 15845615 DOI: 10.1210/En.2005-0103 |
0.626 |
|
| 2005 |
Wu J, Brandt S, Hyder SM. Ligand- and cell-specific effects of signal transduction pathway inhibitors on progestin-induced vascular endothelial growth factor levels in human breast cancer cells. Molecular Endocrinology (Baltimore, Md.). 19: 312-26. PMID 15528272 DOI: 10.1210/Me.2004-0252 |
0.496 |
|
| 2004 |
Uray IP, Liang Y, Hyder SM. Estradiol down-regulates CD36 expression in human breast cancer cells. Cancer Letters. 207: 101-7. PMID 15050739 DOI: 10.1016/J.Canlet.2003.10.021 |
0.491 |
|
| 2004 |
Wu J, Richer J, Horwitz KB, Hyder SM. Progestin-dependent induction of vascular endothelial growth factor in human breast cancer cells: preferential regulation by progesterone receptor B. Cancer Research. 64: 2238-44. PMID 15026368 DOI: 10.1158/0008-5472.Can-03-3044 |
0.567 |
|
| 2002 |
Hyder SM, Stancel GM. Inhibition of progesterone-induced VEGF production in human breast cancer cells by the pure antiestrogen ICI 182,780. Cancer Letters. 181: 47-53. PMID 12430178 DOI: 10.1016/S0304-3835(02)00048-4 |
0.623 |
|
| 2002 |
Hyder SM. The role of steroid hormones on the regulation of vascular endothelial growth factor. The American Journal of Pathology. 161: 345-6. PMID 12107119 DOI: 10.1016/S0002-9440(10)64186-7 |
0.372 |
|
| 2001 |
Hyder SM, Chiappetta C, Stancel GM. Pharmacological and endogenous progestins induce vascular endothelial growth factor expression in human breast cancer cells International Journal of Cancer. 92: 469-473. PMID 11304678 DOI: 10.1002/Ijc.1236 |
0.562 |
|
| 2001 |
Krumenacker JS, Hyder SM, Murad F. Estradiol rapidly inhibits soluble guanylyl cyclase expression in rat uterus Proceedings of the National Academy of Sciences of the United States of America. 98: 717-722. PMID 11209068 DOI: 10.1073/Pnas.98.2.717 |
0.345 |
|
| 2000 |
Hyder SM, Huang JC, Nawaz Z, Boettger-Tong H, Mäkelä S, Chiappetta C, Stancel GM. Regulation of vascular endothelial growth factor expression by estrogens and progestins Environmental Health Perspectives. 108: 785-790. PMID 11035983 DOI: 10.2307/3454307 |
0.5 |
|
| 2000 |
Nephew KP, Ray S, Hlaing M, Ahluwalia A, Wu SD, Long X, Hyder SM, Bigsby RM. Expression of estrogen receptor coactivators in the rat uterus. Biology of Reproduction. 63: 361-7. PMID 10906038 DOI: 10.1095/Biolreprod63.2.361 |
0.364 |
|
| 2000 |
Hyder SM, Chiappetta C, Stancel GM. Induction of the angiogenic factor VEGF in the uterus by the antiprogestin onapristone Cancer Letters. 156: 101-107. PMID 10840165 DOI: 10.1016/S0304-3835(00)00448-1 |
0.444 |
|
| 2000 |
Hyder SM, Stancel GM. Regulation of VEGF in the reproductive tract by sex-steroid hormones. Histology and Histopathology. 15: 325-34. PMID 10668221 DOI: 10.14670/Hh-15.325 |
0.443 |
|
| 1999 |
Hyder SM, Stancel GM. Regulation of angiogenic growth factors in the female reproductive tract by estrogens and progestins. Molecular Endocrinology (Baltimore, Md.). 13: 806-11. PMID 10379879 DOI: 10.1210/Mend.13.6.0308 |
0.404 |
|
| 1999 |
Hyder SM, Chiappetta C, Stancel GM. Interaction of human estrogen receptors α and β with the same naturally occurring estrogen response elements Biochemical Pharmacology. 57: 597-601. PMID 10037443 DOI: 10.1016/S0006-2952(98)00355-4 |
0.321 |
|
| 1997 |
Hyder SM, Chiappetta C, Stancel GM. Triphenylethylene antiestrogens induce uterine vascular endothelial growth factor expression via their partial estrogen agonist activity Cancer Letters. 120: 165-171. PMID 9461033 DOI: 10.1016/S0304-3835(97)00306-6 |
0.496 |
|
| 1996 |
Hu C, Hyder SM, Needleman DS, Baker VV. Expression of estrogen receptor variants in normal and neoplastic human uterus. Molecular and Cellular Endocrinology. 118: 173-9. PMID 8735603 DOI: 10.1016/0303-7207(96)03780-X |
0.388 |
|
| 1995 |
Stancel GM, Boettger-Tong HL, Chiappetta C, Hyder SM, Kirkland JL, Murthy L, Loose-Mitchell DS. Toxicity of endogenous and environmental estrogens: What is the role of elemental interactions? Environmental Health Perspectives. 103: 29-33. PMID 8593870 DOI: 10.1289/Ehp.95103S729 |
0.348 |
|
| 1995 |
Hyder SM, Stancel GM, Loose-Mitchell DS. Steroid hormone-induced expression of oncogene encoded nuclear proteins. Critical Reviews in Eukaryotic Gene Expression. 4: 55-116. PMID 7987047 DOI: 10.1615/Critreveukargeneexpr.V4.I1.30 |
0.309 |
|
| 1995 |
Hyder SM, Nawaz Z, Chiappetta C, Yokoyama K, Stancel GM. The protooncogene c-jun contains an unusual estrogen-inducible enhancer within the coding sequence Journal of Biological Chemistry. 270: 8506-8513. PMID 7721748 DOI: 10.1074/Jbc.270.15.8506 |
0.348 |
|
| 1995 |
Hyder SM, Shipley GL, Stancel GM. Estrogen action in target cells: selective requirements for activation of different hormone response elements Molecular and Cellular Endocrinology. 112: 35-43. PMID 7589783 DOI: 10.1016/0303-7207(95)03581-Q |
0.406 |
|
| 1994 |
Hyder SM, Stancel GM. In vitro interaction of uterine estrogen receptor with the estrogen response element present in the 3'-flanking region of the murine c-fos protooncogene. The Journal of Steroid Biochemistry and Molecular Biology. 48: 69-79. PMID 8136308 DOI: 10.1016/0960-0760(94)90252-6 |
0.323 |
|
| 1993 |
Nawaz Z, Stancel GM, McDonnell DP, Hyder SM. Creation of an active estrogen-responsive element by a single base change in the flanking sequence of a cellular oncogene: A possible mechanism for hormonal carcinogenesis? Molecular Carcinogenesis. 7: 76-82. PMID 8457291 DOI: 10.1002/Mc.2940070204 |
0.39 |
|
| 1992 |
Hyder SM, Stancel GM, Loose-Mitchell DS. Presence of an estradiol response region in the mouse c-fos oncogene. Steroids. 56: 498-504. PMID 1805451 DOI: 10.1016/0039-128X(91)90114-B |
0.331 |
|
| 1983 |
Hyder S, Leake R. 104 Heterogeneity of low salt 4S oestrogen receptor from human breast cancer with respect to DNA binding Journal of Steroid Biochemistry. 19: 35. DOI: 10.1016/0022-4731(83)91604-7 |
0.386 |
|
| 1982 |
HYDER SM, LEAKE RE. Stability of transformed oestrogen receptor from human endometrium and breast carcinoma Biochemical Society Transactions. 10: 522-523. DOI: 10.1042/bst0100522 |
0.301 |
|
| Show low-probability matches. |